Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VIMSELTINIB vs VISIPAQUE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

VIMSELTINIB vs VISIPAQUE: Safety Overview

Metric VIMSELTINIB VISIPAQUE
Total FAERS Reports 170 136
Deaths Reported 0 3
Death Rate N/A 2.2%
Hospitalizations 5 40
Average Patient Age 45.6 yrs 58.0 yrs
% Female Patients 55.4% N/A
FDA Approval Date Feb 14, 2025 N/A
Manufacturer Deciphera Pharmaceuticals, LLC N/A
Route ORAL N/A
Marketing Status Prescription N/A